| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. | J Natl Cancer Inst | 2006 | 2.61 |
| 2 | What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). | Cancer Invest | 2003 | 1.49 |
| 3 | Medical and nursing education and training opportunities to improve survivorship care. | J Clin Oncol | 2006 | 1.32 |
| 4 | Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. | Am J Clin Oncol | 2003 | 0.75 |